Shanghai Henlius Biotech Inc. signed an exclusive licensing deal with Organon LLC under which Organon will in-license rights for two of Henlius’ internally developed biosimilar candidates for global commercialization, excluding China, Hong Kong, Macau and Taiwan. Read More
Daiichi Sankyo Co. Ltd.’s quizartinib met the primary endpoint of overall survival in the pivotal phase III Quantum-First study, which tested the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). Read More
Everest Medicines Ltd. has picked up its first marketing approval in China for Trodelvy (sacituzumab govitecan), a medicine licensed from Gilead Sciences Inc. It was approved to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease. Read More
Jiangsu Hengrui Medicine Co. Ltd., its subsidiary Shengdi Investment Management Holding Co. Ltd., and Hengrui Group are to invest ¥2.01 billion (US$301 million) to jointly set up an equity investment company targeting pharmaceutical and health care companies. Read More
Profoundbio Inc. closed a $70 million series A financing round that will see it advance its two lead antibody-drug conjugate (ADC) programs to the clinic. The Suzhou, China, and Woodinville, Wash.-based company has raised a total of more than $138 million in the past two years. Read More
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies. Read More
Hua Medicine Ltd. presented findings from two phase III trials of its first-in-class dual-acting glucokinase activator dorzagliatin that show the drug significantly improved early phase insulin secretion and glucose sensitivity in patients with type 2 diabetes, thereby restoring glucose homeostasis to treat the underlying cause of diabetes. Read More
A lot of eyes are on the World Trade Organization (WTO) Ministerial Conference taking place in Geneva June 12-15, as member countries try to reach a consensus on a proposal that would allow certain members to waive intellectual property (IP) rights on COVID-19 vaccines for at least three to five years. Read More
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Akeso, Alphamab Oncology, Amgen, Ascentage, Astrazeneca, Bristol Myers Squibb, Carsgen, Cstone, Daiichi Sankyo, Eisai, Henlius, Immutep, Innovent Biologics, Jacobio, JW, Kyowa Kirin, MEI, Oricell, Takeda. Read More
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Kyowa Kirin, MEI. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Brii, Immunome, Innocare, Kazia, Keymed, Medicinova, Merck, Moderna, Ridgeback, Rigel, Takeda, Tevogen. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aslan, Aurigene Discovery Technologies, Chromadex, Cyanvac, Emergent Biosolutions, Ferring, Gritstone, I-Mab, Janssen, Johnson & Johnson, Kazia, Multitude, Olema, Oncusp, Pfizer, Qualigen. Read More
